CGRP monoclonal antibody use in Japan

Keiko Ihara, MD, Keio University School of Medicine, Tokyo, Japan, discusses calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) use in Japan. According to Japanese Headache Society guidelines, CGRP mAbs can be prescribed to patients who have ≥ 4 monthly migraine days and ≥ 1 previous preventive failure. To understand the actual use of CGRP mAbs, Dr Ihara and her team conducted an online survey of ~400 Japanese Headache Society members. Most of the respondents recommended CGRP mAbs to patients with ≥ 2 preventive failures. Dr Ihara highlights that cost was found to be a significant limiting factor in the prescription of the CGRP mAbs.
This interview took place at the American Headache Society (AHS) Annual Meeting 2024 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.